- Home
- YORW vs ADCT Comparison
YORW vs ADCT Comparison
Compare YORW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YORW
- ADCT
- Stock Information
- Founded
- YORW 1816
- ADCT 2011
- Country
- YORW United States
- ADCT Switzerland
- Employees
- YORW N/A
- ADCT N/A
- Industry
- YORW Water Supply
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- YORW Utilities
- ADCT Health Care
- Exchange
- YORW Nasdaq
- ADCT Nasdaq
- Market Cap
- YORW 450.2M
- ADCT 454.5M
- IPO Year
- YORW N/A
- ADCT 2020
- Fundamental
- Price
- YORW $32.25
- ADCT $4.11
- Analyst Decision
- YORW
- ADCT Strong Buy
- Analyst Count
- YORW 0
- ADCT 6
- Target Price
- YORW N/A
- ADCT $7.60
- AVG Volume (30 Days)
- YORW 99.3K
- ADCT 745.9K
- Earning Date
- YORW 11-06-2025
- ADCT 11-10-2025
- Dividend Yield
- YORW 2.72%
- ADCT N/A
- EPS Growth
- YORW N/A
- ADCT N/A
- EPS
- YORW 1.39
- ADCT N/A
- Revenue
- YORW $76,882,000.00
- ADCT $75,209,000.00
- Revenue This Year
- YORW $7.50
- ADCT $11.78
- Revenue Next Year
- YORW $6.33
- ADCT $4.83
- P/E Ratio
- YORW $23.17
- ADCT N/A
- Revenue Growth
- YORW 3.63
- ADCT 6.35
- 52 Week Low
- YORW $29.68
- ADCT $1.05
- 52 Week High
- YORW $36.60
- ADCT $4.80
- Technical
- Relative Strength Index (RSI)
- YORW 53.41
- ADCT 50.55
- Support Level
- YORW $31.60
- ADCT $3.87
- Resistance Level
- YORW $32.40
- ADCT $4.19
- Average True Range (ATR)
- YORW 0.85
- ADCT 0.30
- MACD
- YORW -0.03
- ADCT -0.04
- Stochastic Oscillator
- YORW 57.07
- ADCT 42.31
About YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).